SARS-CoV-2 Safety Study for the Treatment of COVID-19

DHA Coffee Co., Ltd

Status and phase: Withdrawn; Phase 2

Conditions: SARS-CoV-2

Treatments: Drug: HIV; Drug: Malignant Neoplasms Safety Study for the Treatment of Neoplasms

Study type: Interventional

Funder types: Industry

Identifiers

NCT06489860

DHACoffee

Details and patient eligibility

About

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Full description

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells.

CHEMISTRY:

SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives.

Toxicology:

SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology.

SARS-CoV-2 is not placebo drug

Sex: All

Ages: 1 to 130 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• SARS-CoV-2

Exclusion Criteria:

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

SARS-CoV-2 Safety Study for the Treatment of COVID-19

Experimental group

Description:

Directions: For adults and for Children 1-12 years old. Indication:SARS-CoV-2 Ingredients: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

Treatment:

Drug: Malignant Neoplasms Safety Study for the Treatment of Neoplasms

Drug: HIV